Pharmaceutical compositions comprising flavonoids and menthol

• US 7,585,890 B2
• Filed: 09/19/2003
• Issued: 09/08/2009
• Est. Priority Date: 10/24/2002
• Status: Expired due to Fees

• Current Assignee: Immunpharm A/S
• Original Assignee: Immunpharm A/S
• Inventors: Berg, Kurt Frimann
• Primary Examiner(s): Solola; Taofiq A
• Application Number:
  US10/532,341
• Publication Number:
  US 20060148726A1
• Time in Patent Office: 2,181 Days
• Field of Search: 514/456
• US Class Current: 514/456
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/045 Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61K 31/315 Zinc compounds
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses

Abstract

The present invention relates to use of certain antiviral fragrances for reduction of viruses, in particular vira causing common cold. In one embodiment, the invention relates to pharmaceutical compositions comprising an antiviral fragrance, preferably menthol. Said compositions preferably also comprise one or more flavonoids. The invention also relates to treatment of common cold using said compositions.

Claims

1. A pharmaceutical composition comprising

one or more purified flavonoids;

and

purified menthol, in a state of purity such that the purified menthol has a direct antiviral effect in vitro on rhinovirus in WISH cells, or potentiates the antiviral effect in vitro of human interferon -α

-2b (Intron A) on rhinovirus in WISH cells.

2. The pharmaceutical composition according to claim 1, wherein said composition also comprises a pharmaceutically acceptable metal complex and/or metal salt.

3. The pharmaceutical composition according to claim 2, wherein said metal is zinc.

4. The pharmaceutical composition according to claim 2, wherein the metal is zinc selected from the group consisting of Zn²⁺ aminochelates , Zn²⁺ amino acid chelates, Zn(acetate)₂, Zn²⁺ DL-methionine, Zn²⁺ L-methionine, ZnGluconate and PolaPreZinc®

.

5. The pharmaceutical composition according to claim 1, wherein said composition is useful for oral and/or nasal administration.

6. The pharmaceutical composition according to claim 1, wherein said composition is selected from the group consisting of lozenges, troches, capsules, syrups, tablets, lollipops, solutions, dispersions, suspensions, powders, micropheres, chewing tablets, chewing gums, sprays, droppers, pipettes and pills.

7. The pharmaceutical composition according to claim 1, wherein said composition is a slow-release composition.

8. The pharmaceutical composition according to claim 1, wherein said composition is lozenges.

9. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of crude plant extracts.

10. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of other terpenes than menthol.

11. The pharmaceutical composition according to claim 1, wherein said composition is essentially free of one or more compounds selected from the group consisting of menthone, menthyl acetate, limonene and neomenthol.

12. The pharmaceutical composition according to claim 1, wherein one or more flavonoids are chelating a metal.

13. The pharmaceutical composition according to claim 1, wherein the metal is Zn²⁺.

14. The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of flavonoids of the general formula:

15. The pharmaceutical composition according to claim 1, wherein the flavonoid is selected from the group consisting of troxerutin, venoruton, hesperitin, naringenin, nobiletin, tangeritin, baicalein, galangin, genistein, quercetin, apigenin, kaempferol, fisetin, rutin, luteolin, chrysin, taxifolin, eriodyctol, catecithin, epicatechin gallate, epigallocatechin gallate, flavone, sideritoflavone, hypolaetin-8-O-Gl, oroxindin, 3-hydroxyflavone, morin, quercetagetin-7-O-Gl, tarnbuletin, gossypin, hipifolin, naringin, leucocyanidol, amentoflavone and derivatives thereof and mixtures thereof.

16. The pharmaceutical composition according to claim 1, wherein said flavonoid is not a naturally occurring flavonoid.

17. The pharmaceutical composition according to claim 1, wherein said flavonoid is a rutoside.

18. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a rutoside aglycone.

19. The pharmaceutical composition according to claim 1, wherein said flavonoid is a hydroxyethylrutoside.

20. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is a hydroxyethythyrutoside aglycone.

21. The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of hydroxyethylrutosides.

22. The pharmaceutical composition according to claim 1, wherein said composition comprises a mixture of mono-, di-, tri- and tetrahydroxyethylrutosides.

23. The pharmaceutical composition according to claim 1, wherein at least one flavonoid is troxerutin.

24. The pharmaceutical composition according to claim 1, where at least one flavonoid is troxerutin aglycone.

25. The pharmaceutical composition according to claim 1, wherein the flavonoid is veneruton.

26. The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 90% pure.

27. The pharmaceutical composition according to claim 1, wherein the composition is in a form suitable for nasal administration.

28. The pharmaceutical composition according to claim 27, wherein the composition is in a form suitable for aerosol administration.

29. The pharmaceutical composition according to claim 28, wherein the composition is provided in a pressurized pack which further comprises a propellant.

30. The pharmaceutical composition according to claim 1, wherein said purified menthol is at least 98% pure.